Table 4.
Additional patient demographics and disease characteristics
| Characteristics, n (%) | N = 168 |
|---|---|
| Prior surgery | 161 (95.8) |
| Prior radiotherapy | 139 (82.7) |
| Prior anticancer therapies in any setting | |
| 1 | 5 (3.0) |
| 2 | 27 (16.1) |
| ≥ 3 | 136 (80.9) |
| Median (range) | 4.0 (1–10) |
| Prior platinum regimen | |
| Carboplatin based | 36 (21.4) |
| Cisplatin based | 9 (5.4) |
| Type of prior anticancer therapy | |
| Chemotherapy | 168 (100.0) |
| Hormonal therapy | 103 (61.3) |
| Antibody therapy | 30 (17.9) |
| Kinase inhibitor | 19 (11.3) |
| Vaccines | 1 (0.6) |
| Other | 36 (21.4) |
| Intent of any prior therapy | |
| Neoadjuvant | 64 (38.1) |
| Adjuvant | 111 (66.1) |
| Metastatic | 137 (81.5) |
| Locally advanced | 30 (17.9) |
| Palliative | 7 (4.2) |
| Best response to any prior anticancer therapy | |
| Complete response | 3 (1.8) |
| Partial response | 9 (5.4) |
| Stable disease | 33 (9.6) |
| Progressive disease | 94 (56.0) |
| Not assessable | 1 (0.6) |
| Unknown | 13 (7.7) |
| Not applicable | 15 (8.9) |